

**INDEPENDENT AUDITOR'S REPORT**

TO  
THE MEMBERS OF  
ASSAM MEDICAL SERVICES CORPORATION LIMITED  
GUWAHATI

Report on the standalone Financial Statements

Qualified Opinion

We have audited the accompanying Standalone financial statements of ASSAM MEDICAL SERVICES CORPORATION LIMITED ("the Company") which comprises the Balance Sheet as at March 31, 2023, the Statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, except for obtaining confirmation certificate referred to in the Basis for Qualified Opinion, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with accounting principles generally accepted in India, of the state of affairs of the Company as at 31<sup>st</sup> March, 2023, its profit/loss and its cash flows for the year ended on that date.

Basis for Qualified Opinion

Our Qualified Opinion on the financial statements of the Corporation is based on the following facts and circumstances:

1) The Govt. grant received has wrongly been shown as equities in the Financial Statement of the corporation which has been detailed as below.

Opening Balance- Rs 5,50,00,000

Addition during the year- Rs 3,04,00,000

No Form PAS-3 (Return of allotment) is filled with Registrar of Companies till date in regard to the above addition made to the equity in the Financial Statement and so no allotment of these shares made till date.

Further as per Accounting Standard-12, the above grant in aid is to be shown under capital reserve in the balance sheet under Capital approach in absence of any information provided by the management in regard to the nature and purpose of



*Govt. grant received. To that extent Equity capital is overstated and capital reserve is understated.*

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

**Key Audit Matters**

Key Audit Matters are those matters that in our professional judgment were of most significant on our Audit of the Standalone Financial Statements as a whole and informing our opinion thereon and we do not provide a separate opinion on these matters in the addition to the matters contained in the Basis for Opinion and Emphasis of Matters sections.

**Information other than the financial statements and auditors' report thereon**

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to the Board's Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.



#### **Responsibility of Management for the Standalone Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.

#### **Auditor's Responsibility for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those





risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in



our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

**Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure-A", a statement on the matters specified in paragraphs 3 & 4 of the Order.
2. As required by Section 143(3) of the Act, we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c. The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account except to the extent stated in our basis of qualified opinion section of this report.
  - d. For the reason stated in our Basis of Qualified Opinion of this report we are unable to comment on whether, the aforesaid standalone financial statements comply with the Companies (Accounting Standards) Rules, 2021 specified under section 133 of the Act, read with the Companies (Accounts) Rules, 2014.
  - e. The company has stated that no such directors was disqualified during the year. As per Notification Number G.S.R. 463(E) dated 5<sup>th</sup> June, 2015 issued by the Ministry of Corporate Affairs, section 164(2) of the Act regarding the disqualification of the directors is not applicable to the Company since it is a Government Company.
  - f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
  - g. In our opinion, the managerial remuneration for the year ended March 31, 2023 has been provided by the Company to its directors in accordance with the provisions of section 197 read with Schedule V to the Act.
  - h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:



# AJP & CO

## CHARTERED ACCOUNTANTS

Email: [ajpghy@gmail.com](mailto:ajpghy@gmail.com)

Head Office : 3<sup>rd</sup> Floor, K.K.Choudhury Commercial Complex  
Near Andhra Bank, Opp. Police Reserve  
A.T.Road, Guwahati  
PIN: 781001, Assam  
Contact : +91 94352 15045

- i. The Company does not have any pending litigations which would impact its financial position;
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
  - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company;
3. As required by section 143(5) of the Act, directions and sub-direction issued by the Comptroller and Auditor General of India, we give our comments thereon in the "Annexure-C"



PLACE : GUWAHATI  
DATE : 06.03.2024  
UDIN : 24301862BKHRQT9263

For AJP & Co  
CHARTERED ACCOUNTANTS  
FIRM REGN. NO. 317033E

*Pankaj Agarwal*  
(PANKAJ AGARWALA)  
PARTNER(M.NO.301862)



### Annexure – 'A' to the Independent Auditor's Report

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of ASSAM MEDICAL SERVICES CORPORATION LIMITED of even date)

In terms of the information and explanations sought by us and given by the company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

- i (a) (A) The Company has not maintained proper records showing full particulars including quantitative details and situation of its Fixed Assets.  
(B) As informed to us by the management and on the basis of our examination of records, the company does not have any intangible assets.
- i (b) As explained to us, fixed assets have not been physically verified by the management at reasonable intervals.
- i (c) As informed to us by the management and on the basis of our examination of records, the following property accounts for in the books of Accounts of the company but not held in its name.

Description of the Property	Gross Carrying amount (in Rs.)	Held in the name of	Whether title ded holder is a promoter, director or Relative of Promoter/direct or or employee of promoter/direct or	Period held	Reason for not being held in the name of the company
Building (Part of Ground floor and Second Floor) and	21263813	Health and Family Welfare Department, Govt of Assam	Not Applicable	NA	It is Government property under the Health and Family



Central Drugs Warehouse campus Patharquar y, Narengi, Guwahati – 781026]					Welfare Deptt. And handed over to AMSCL for use of office and Building.
---	--	--	--	--	--

- i (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not revalued its Property, Plant and Equipment during the year ended March 31, 2023.
- i (e) According to the information and explanations given to us, no proceedings have been initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 (as amended in 2016) and rules made thereunder.
- ii (a) According to the information and explanations given to us on the basis of our examination of records, the company till the year under audit has neither purchased or sold anything under its revenue account and therefore has no inventory during the year and also at the end of the year, hence para 3(ii)(a) of the order is not applicable to the company.
- ii (b) As per the information and explanations given to us and on the basis of our examination of records, the company has not been sanctioned working capital from banks or financial institution. Accordingly, reporting under clause 3(ii)(b) of the order is not applicable to the company.
- iii (a) According to the information and explanation given to us the Company has not provided any guarantee or security or granted any loans or advances in nature of loan, secured or unsecured to companies, firms, Limited Liability partnerships or any other parties during the year and accordingly, the provisions of clause 3 (iii) (a) to (f) of the Order are not applicable to the Company.





- iv According to information and explanations given to us, the company has not either directly or indirectly, granted any loan to any of its director or to any person in whom the director is interested, in accordance to the provisions of sections 185 and 186 of the Companies Act, 2013. Accordingly reporting under clause 3(iv) of the Order is not applicable to the company.
- v The Company has neither accepted any deposits from the public nor accepted any amounts which are deemed to be deposits within the meaning of sections 73 to 76 of the Companies Act and the rules made thereunder, to the extent applicable. Accordingly, the requirement to report on clause 3(v) of the Order is not applicable to the Company.
- vi As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.
- vii (a) According to information and explanations given to us, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax and any other statutory dues with the appropriate authorities. Further, no undisputed amounts payable in respect thereof were outstanding at the year end for a period of more than six months from the date they became payable.
- (b) According to the information and explanation given to us, there is no amount payable in respect of income tax, service tax, sales tax, custom duty, excise duty, value added tax and cess whichever is applicable, which have not been deposited on account of any disputes.
- viii The Company has not surrendered or disclosed any transaction, previously unrecorded in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year. Accordingly, the requirement to report on clause 3(viii) of the Order is not applicable to the Company.
- ix. According to the information and explanations given by the management, the company has not obtained any loans from any financial institution, bank and Government or has not issued any debenture. Accordingly reporting under clause 3(ix) (a) to (f) of the order is not applicable to the company.



- x (a) The Company has not raised any money during the year by way of initial public offer / further public offer (including debt instruments) hence, the requirement to report on clause 3(x)(a) of the Order is not applicable to the Company.
- x (b) The Company has not made any preferential allotment or private placement of shares /fully or partially or optionally convertible debentures during the year under audit and hence, the requirement to report on clause 3(x)(b) of the Order is not applicable to the Company.
- xi (a) Based upon the audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to the information and explanations given by the management, we report that No fraud/ material fraud by the Company or no fraud / material fraud on the Company has been noticed or reported during the year.
- xi (b) During the year, no report under sub-section (12) of section 143 of the Companies Act, 2013 has been filed by cost auditor/ secretarial auditor or by us in Form ADT – 4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- xi (c) As represented to us by the management, there are no whistle blower complaints received by the company during the year.
- xii The Company is not a Nidhi Company as per the provisions of the Companies Act, 2013. Therefore, the requirement to report on clause 3(xii)(a) to 3(xii)(c) of the Order is not applicable to the Company.
- xiii According to the information and explanation given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the financial statements, as required by the applicable accounting standards.
- xiv (a) Based on the information and explanation provided to us and our audit procedure,  
in our opinion the Company has an internal audit system commensurate with the size and nature of its business.
- (b) We have considered the internal audit report of the company issued till date for the period under audit.



- xv In our opinion and according to the information and explanation given to us, the Company has not entered into any non-cash transactions with its directors or persons connected with its directors and hence requirement to report on clause 3(xv) of the Order is not applicable to the Company.
- xvi The provisions of section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934) are not applicable to the Company. Accordingly, the requirement to report on clause 3(xvi)(a) to 3(xvi)(d) of the Order is not applicable to the Company.
- xvii According to the information and explanation given to us, the company has not incurred cash losses in the Financial Year and in the immediately preceding Financial Year.
- xviii There has been no resignation of the statutory auditors during the year and accordingly requirement to report on Clause 3(xviii) of the Order is not applicable to the Company.
- xix According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.
- xx The provisions of Section 135 to the Companies Act, 2013 in relation to Corporate Social Responsibility is not applicable to the Company. Accordingly, the requirement to report on clause 3(xx)(a) and 3(xx)(b) of the Order is not applicable to the Company.





- xxi The reporting under clause 3(xxi) of the Order is not applicable in respect of audit of Standalone Financial Statements. Accordingly, no comment in respect of the said clause has been included in this report.



PLACE : GUWAHATI

DATE : 06.03.2024

UDIN : 243018628KHRQT9263

For A J P & Co  
CHARTERED ACCOUNTANTS  
FIRM REGN. NO. 317033E

*Pankaj Agarwal*  
(PANKAJ AGARWALA)  
PARTNER(M.NO.301862)

### **Annexure – ‘B’ to the Independent Auditor’s Report**

(Referred to in paragraph 2(f) under ‘Report on Other Legal and Regulatory Requirements’ section of our report to the Members of ASSAM MEDICAL SERVICES CORPORATION LIMITED of even date)

#### **Report on the internal financial controls under clause (i) of sub-section 3 of section 143 of the Companies Act, 2013 (“the act”)**

We have audited the internal financial controls over financial reporting of ASSAM MEDICAL SERVICES CORPORATION LIMITED (“the Company”) as of 31<sup>st</sup> March, 2023 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

#### **Management’s Responsibility for Internal Financial Controls**

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (“ICAI”). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditors’ Responsibility**

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness.



Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

#### **Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

#### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

#### **Qualified Opinion**

In our opinion, to the best of our information and according to explanation given to us subject to our comment given "Based of Qualified opinion paragraph" the Company has, in all material respects, an adequate internal financial controls system over financial reporting and





such internal financial controls over financial reporting were operating effectively as at 31<sup>st</sup> March, 2023, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.



PLACE : GUWAHATI

DATE : 06.03.2024

UDIN : 24301862BKHRQT9263

For AJP & Co  
CHARTERED ACCOUNTANTS  
FIRM REGN. NO. 317033E

*Pankaj Agarwal*

(PANKAJ AGARWALA)

PARTNER(M.NO.301862)

### Annexure "C" to Independent Auditors Report

(Referred to in paragraph 3 under "Report on other Legal and Regulatory Requirements" of our Report of even date to the members of ASSAM MEDICAL SERVICES CORPORATION LIMITED on the standalone financial statements for the year ended 31<sup>st</sup> March, 2023

Sl No	Directions	Comments
1	Whether the company has system in place to process all the accounting transactions through IT system? If yes, the implications of processing of accounting transactions outside IT system on the integrity of the accounts along with the financial implications, if any, may be stated.	The company is using Tally Software for maintaining of accounts but it is not full proof system with audit trail etc.
2	Whether there is any restructuring of an existing loan or cases of waiver/write off of debts loans/interest etc. made by a lender to the company due to the company's inability to repay the loan? If yes, the financial impact may be stated.	According to the information and explanation given to us and based on the examination of the records, there are no case of waiver/write off of debt/loans/interest etc. during the year.
3	Whether funds received/receivable for specific schemes from central/ state agencies were properly accounted for/ utilized as per its term and conditions? List the cases of deviation	Properly accounted for/utilized except as mentioned in the "Basis of Qualified Opinion" para of the main audit report.



PLACE : GUWAHATI

DATE : 06.03.2024

UDIN : 24301862BKHRQT9263

For A J P & Co  
CHARTERED ACCOUNTANTS  
FIRM REGN. NO. 317033E

*Pankaj Agarwala*  
(PANKAJ AGARWALA)  
PARTNER(M.NO.301862)

**ASSAM MEDICAL SERVICES CORPORATION LIMITED**  
CENTRAL DRUG WAREHOUSE, NARENGI, GUWAHATI - 781 026, ASSAM

**BALANCE SHEET AS AT 31ST MARCH 2023**

		(Amount in Rupees Lakhs)	
PARTICULARS	Note No.	31st March 2023	31st March 2022
<b>I EQUITY AND LIABILITIES</b>			
<b>1 Shareholders Funds</b>			
a) Share Capital	2	854.00	550.00
b) Reserve & Surplus	3	(237.11)	(40.89)
c) Money received against share warrants			
<b>2 Share Application money pending allotment</b>			
<b>3 Non-current Liabilities</b>			
a) Long Term Borrowings		-	-
b) Deferred Tax Liabilities (Net)	4	6.02	-
c) Other Long Term Liabilities		-	-
d) Long Term Provisions		-	-
<b>4 Current Liabilities</b>			
a) Short Term Borrowings		-	-
b) Trade Payables	5	-	-
(i) Outstanding due of micro and small enterprise			
(ii) Other than micro and small enterprise		63.22	4.99
c) Other Current Liabilities	6	29,893.56	1.35
d) Short Term Provisions		-	-
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>30,579.70</b>	<b>515.45</b>
<b>II ASSETS</b>			
<b>1 Non-current Assets</b>			
a) Property Plant & Equipment and Intangible Assets			
i) Property, Plant & Equipment	7	245.03	11.16
ii) Intangible assets			
iii) Capital Work in progress	8		209.58
iv) Intangible assets under development			
b) Non-current investments		-	-
c) Deferred tax assets (net)		-	1.90
d) Long Term Loans & advances		-	-
e) Other non-current assets		-	-
<b>2 Current Assets</b>			
a) Current Investments		-	-
b) Inventories		-	-
c) Trade Receivables		-	-
d) Cash and Cash equivalents	9	30,317.46	290.66
e) Short Term Loans and Advances	10	16.29	-
f) Other Current Assets	11	0.92	2.15
<b>TOTAL ASSETS</b>		<b>30,579.70</b>	<b>515.45</b>

Significant Accounting policies

1 to 15

The accompanying notes form an integral part of the Financial Statements

In terms of our REPORT of even date annexed hereto,

For A J P & CO.

Chartered Accountants

Firm Registration No : 3170335

*Pankaj Agarwal*

Pankaj Agarwal

Partner (M.No 301862)

Place: Guwahati

Date: 06/03/2024



For Assam Medical Services Corporation Ltd

(CIN: U85300AS2018SGC017461)

*Dr Robin Kumar*

(Dr Robin Kumar)

Managing Director

DIN: 09442400

*Pranati Majumdar*

(Pranati Majumdar)

Additional MD

DIN: 09630322

**Managing Director**  
**ASSAM MEDICAL SERVICES**  
**CORPORATION LTD**

**Addl. Managing Director**  
**ASSAM MEDICAL SERVICE**  
**CORPORATION LTD.**



ASSAM MEDICAL SERVICES CORPORATION LIMITED  
CENTRAL DRUG WAREHOUSE, NARENGI, GUWAHATI - 781 026, ASSAM

**STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

		(Amount in Rupees Lakhs)	
PARTICULARS	Note No.	31st March 2023	31st March 2022
1 Revenue from Operations		-	-
Less Excise Duty		-	-
2 Other income	12	8.71	2.19
3 Total Income (1+2)		8.71	2.19
4 Expenses			
Cost of materials consumed		-	-
Other manufacturing expenses		-	-
Purchases of stock in trade		-	-
Changes in inventories of finished goods, work in progress and stock in trade		-	-
Employees benefit expenses	13	60.35	-
Finance Cost		-	-
Depreciation and amortization expenses	7	6.81	0.30
Other expenses	14	129.86	23.15
Total Expenses		197.01	23.44
5 Profit before exceptional and extraordinary items and tax (3-4)		(188.30)	(21.25)
6 Exceptional Items/Prior Period Item-Depreciation		-	-
7 Profit before extraordinary items and tax (5-6)		(188.30)	(21.25)
8 Extraordinary Items		-	-
9 Profit before tax (7-8)		(188.30)	(21.25)
10 Tax Expenses			
i) Current Tax expenses for current year		-	-
ii) Current Tax expenses relating to prior years		-	-
ii) Deferred Tax		(7.92)	(0.34)
11 Profit (Loss) for the period from Continuing operations (9-10)		(196.22)	(21.59)
12 Earning per share (in Rs)			
Basic & Diluted		(22.98)	(3.93)

Significant Accounting policies

1 to 15

The accompanying notes form an integral part of the Financial Statements

In terms of our REPORT of even date annexed hereto.

For A J P & CO.

Chartered Accountants

Firm Registration No : 317033E

*Pankaj Agarwal*

Pankaj Agarwal

Partner (M.No 301862)

Place: Guwahati

Date: 06/03/2024



For Assam Medical Services Corporation Ltd  
(CIN: U85320AS2016SGC017461)

*Dr Robin Kumar*

(Dr Robin Kumar)

Managing Director

DIN: 09442400

*Pranati Majumdar*

(Pranati Majumdar)

Additional MD

DIN: 09630322

Managing Director  
ASSAM MEDICAL SERVICES CORPORATION LTD  
Addl. Managing Director  
ASSAM MEDICAL SERVICES CORPORATION LTD

ASSAM MEDICAL SERVICES CORPORATION LIMITED  
CENTRAL DRUG WAREHOUSE, NARENGI, GUWAHATI - 781 026, ASSAM

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2023

(Amount in Rupees Lakhs)

PARTICULARS	31st March 2023	31st March 2022
<b>A. Cash Flow From Operating Activities</b>		
Net Profit before tax and extraordinary items(as per Statement of Profit and Loss)	(188.30)	(21.25)
Adjustments for non cash/ non trade items:		
Depreciation & Amortization Expenses	6.81	0.30
Finance Cost	-	-
Interest received	(7.69)	-
Provision for employees benefit	-	-
<b>Operating profits before Working Capital Changes</b>	<b>(189.18)</b>	<b>(20.96)</b>
<b>Adjusted For:</b>		
Decrease (increase) in trade receivables	-	-
Increase (decrease) in trade payables	58.23	-
Adjustments for decrease (increase) in Inventories	-	-
Adjustments for increase (decrease) in other current liabilities	29,892.21	3.52
Adjustments for decrease (increase) in other non current assets	-	-
Adjustments for decrease (increase) in Long term provision (Gratuity paid)	-	-
Adjustments for decrease (increase) in Other current assets	1.23	-2.15
<b>Cash generated from Operations</b>	<b>29,762.49</b>	<b>-19.59</b>
Income Tax paid/(refund)	-	-
<b>Net cash flow from operating activities before extraordinary items</b>	<b>29,762.49</b>	<b>-19.59</b>
<b>Net Cash flow from Operating Activities(A)</b>	<b>29,762.49</b>	<b>-19.59</b>
<b>B. Cash Flow From Investing Activities</b>		
Non Current Investments purchased/Sold	-	-
Current Investments purchased/sold	-	-
Interest Received	7.69	-
Cash advances and loans made to other parties	-	-
Increase/Decrease in Short Term Loans & Advances	(16.29)	-
Cash receipts from repayment of advances and loans made to other parties	-	-
Purchasing/sales of PPE	(31.09)	(16.20)
<b>Net cash flow from investing activities before extraordinary items</b>	<b>(39.70)</b>	<b>(16.20)</b>
<b>Net Cash used in Investing Activities(B)</b>	<b>(39.70)</b>	<b>(16.20)</b>
<b>C. Cash Flow From Financing Activities</b>		
Finance Cost	-	-
Increase in/Repayment of Short term Borrowings	-	-
Repayment/Increase of Long term borrowings	-	-
Increase/decrease in share capital	-	-
Increase/decrease in share application money pending allotment	-	-
Receipt of Government Subsidies	304.00	320.00
<b>Net cash flow from investing activities before extraordinary items</b>	<b>304.00</b>	<b>320.00</b>
<b>Net Cash used in Financing Activities(C)</b>	<b>304.00</b>	<b>320.00</b>
<b>D. Net increase/decrease in Cash &amp; Cash Equivalents(A+B+C)</b>	<b>30,026.80</b>	<b>284.21</b>
<b>E. Cash &amp; Cash Equivalents at Beginning of period</b>	<b>290.66</b>	<b>6.45</b>
<b>F. Cash &amp; Cash Equivalents at End of period</b>	<b>30,317.46</b>	<b>290.66</b>
<b>G. Net increase/decrease in Cash &amp; Cash Equivalents(F-E)</b>	<b>30,026.80</b>	<b>284.21</b>


The accompanying notes form an integral part of the Financial Statements

In terms of our REPORT of even date annexed hereto.

For A J P & CO.

Chartered Accountants

Firm Registration No : 317033E

  
Pankaj Agarwal  
Partner (M.No 301862)



Place: Guwahati  
Date: 06/03/2024

For Assam Medical Services Corporation Ltd  
(CIN: U85300AS2016SGC017461)

  
(Dr Robin Kumar)  
Managing Director  
DIN: 09442400

  
(Pranati Majumdar)  
Additional MD  
DIN: 09630322

Managing Director  
ASSAM MEDICAL SERVICES CORPORATION LTD  
Addl. Managing Director  
ASSAM MEDICAL SERVICES CORPORATION LTD.

**ASSAM MEDICAL SERVICES CORPORATION LIMITED**  
**CENTRAL DRUG WAREHOUSE, NARENGI, GUWAHATI - 781 026, ASSAM**  
**CIN: U85320AS2016SGC017461**

**NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31<sup>ST</sup> MARCH 2023 :**

**NOTE 1A: ABOUT THE COMPANY**

Assam Medical Services Corporation Ltd is a Public incorporated on 22-06-2016. It is classified as a State Govt company and is registered at ROC-Shillong. Their state of registration is Assam. Its authorized share capital is 15,00,00,000.

**NOTE 1B: SIGNIFICANT ACCOUNTING POLICIES**

**1. BASIS OF PREPARATION OF FINANCIAL STATEMENT:**

These financial statements have been prepared to comply with the Generally Accepted Accounting Principles in India (Indian GAAP) including the Accounting Standards notified under the relevant provisions of the Companies Act, 2013.

The financial statements are prepared on accrual basis under the historic cost convention. The financial statements are presented in Indian rupees.

**2. USE OF ESTIMATES:**

The preparation of financial statement in conformity with Indian GAAP requires judgments, estimates and assumptions to be made that affect the reported amount of assets and liabilities, disclosure of contingent liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognized in the period in which the results are known/ materialized. The management believes that the estimated used in the preparation of financial statements are prudent and reasonable.

**3. PROPERTY, PLANT AND EQUIPMENT (PPE)**

PPE are initially recognized at cost. The initial cost of PPE comprises its purchase price, borrowing cost and any cost directly attributable to bringing the asset to its working condition for its intended use. PPE are stated at cost less accumulated depreciation and impairment losses, if any.

Subsequent expenditures related to an item of Tangible Assets are added to its book value only if they increase the future benefits from the existing assets beyond its previously assessed standard of performance. All other repairs and maintenance expenses are charged to profit or loss during the reporting period in which they are incurred.

Depreciation on Fixed Assets is provided to the extent of depreciable amount on Written Down Value (WDV) Method. Depreciation is provided based on useful life of the assets as prescribed in Schedule II of the Companies Act, 2013.

**4. IMPAIRMENT OF ASSETS**

An asset is treated as impairment when the carrying cost of assets exceeded its recoverable value. An impairment loss is charged to the profit and loss statement in the year in which an asset is identified as impaired. The impairment loss recognized in prior accounting period is reserved if there has been a change in the estimate of recoverable amount.

**5. LEASES**

Assets taken on lease under which all the risk and rewards of ownership are effectively retained by the lessor are classified as operating lease. Lease payment under operating leases are recognized as expenses on accrual basis with reference to the lease term and other considerations.





**ASSAM MEDICAL SERVICES CORPORATION LIMITED**  
**CENTRAL DRUG WAREHOUSE, NARENGI, GUWAHATI - 781 026, ASSAM**  
**CIN: U85320AS2016SGCD17461**

**6. FOREIGN CURRENCY TRANSACTIONS**

Transaction denominated in Foreign Currency are recorded at the exchange rate prevailing on the date of the transaction. Liabilities and receivables in foreign currency are restated at the year-end exchange rates. All exchange rate differences arising from conversion in terms of the above are included in the statement of profit and loss.

**7. INVENTORIES**

Items of inventories are measured at lower of cost or net realizable value. Cost of inventories comprises of cost of purchase, cost of conversion and other cost including manufacturing overheads incurred in bringing them to their respective condition.

**8. INVESTMENTS**

Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as non-current investments.

Current investments are carried in the financial statements at lower of cost and fair value determined on an individual investment basis. Long-term investments are carried at cost. However, provision for diminutions in value is made to recognize a decline other than temporary in the value of the investments.

On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss.

**9. REVENUE RECOGNITION**

Revenue is recognized only when risk and reward incidental to ownership are transferred to the customer, which generally coincides with the dispatch of goods to customers. Revenue from operation include sale of goods.

Subsidy received against revenue items during the year are treated as other Income in the Profit & Loss Account.

Expenses and Income considered payable and receivable respectively are accounted for on accrual basis.

**10. EMPLOYEES BENEFITS**

Contribution to provident fund, pension fund, Deposit linked and Employees State Insurance are charged to the statement of Profit and Loss as incurred.

Provision for payment of gratuity to the employees has been made in the accounts as per the Payment of Gratuity Act, 1972.

**11. EARNING PER SHARES**

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all diluting potential equity shares.



**ASSAM MEDICAL SERVICES CORPORATION LIMITED**  
**CENTRAL DRUG WAREHOUSE, NARENGI, GUWAHATI - 781 026, ASSAM**  
**CIN: U85320AS2016SGC017461**

**12. BORROWING COSTS**

Borrowing cost that are attributable to the acquisition or construction or production of qualifying assets are capitalized as part of the cost of such assets till such time the assets is ready for intended use or sale. A qualifying asset is an asset that necessarily takes substantial period of time to get ready for its intended use or sale. Any other borrowing costs are recognized as an expense in the period in which they are incurred.

**13. INCOME TAXES**

Tax expense comprises of current tax and deferred tax. Current tax is measured at the amount expected to be paid to the tax authorities using the applicable tax rates.

Deferred income tax reflect current period timing difference between taxable income and accounting income and reversal of timing difference of earlier year/period. Deferred tax assets are recognized only to the extent there is a reasonable certainty that sufficient future income will be available.

Deferred tax assets and liabilities are measured using the tax rates and tax law that have been enacted or substantially enacted by the Balance Sheet date.

**14. PROVISIONS, CONTINGENT LIABILITIES AND CONTINGENT ASSETS**

Provision is recognized in the accounts when there is a present obligation as a result of past event(s) and it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimates required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

Contingent Liabilities is disclosed in Notes to the account for :-

- (i) Possible obligations which will be confirmed only by future events not wholly within the control of the company or
- (ii) Present Obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

Contingent assets are not recognized in the financial statement since this may result in the recognition of the income that may never be realized.

**15. CASH FLOW STATEMENTS**

Cash flow statement is prepared in accordance with the indirect method prescribed in the relevant Accounting Standard.



**ASSAM MEDICAL SERVICES CORPORATION LIMITED**

**NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

(Amount in Rupees Lakhs)

PARTICULARS	31st March 2023	31st March 2022
<b>2 SHARE CAPITAL</b>		
<u>Authorised</u>		
15,00,000 Equity Share of Rs 100/- each	1,500.00	1,500.00
<u>Issued</u>		
2,30,000 Equity Share of Rs 100/- each	854.00	550.00
<u>Subscribed &amp; Fully Paid up</u>		
Equity Share of Rs 100/- each	854.00	550.00
No change in the year and previous year		

**Note No. 2.1 (a) The Reconciliation of the No. of Shares outstanding at the beginning and at the end of the period**

Particulars	Figures as at the end of the current reporting period		Figures as at the end of the previous reporting period	
	No	Amount in lakh	No	Amount in lakh
<b>Equity Shares:</b>				
Shares outstanding at the beginning of the year	5.50	550.00	5.50	550.00
Shares Issued during the year	3.04	304.00	-	-
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	8.54	854.00	5.50	550.00

**Note No. 2.1(b) Discrepancy in amount received as Share Capital**

As per records available with Ministry of Corporate Affairs the issued, subscribed and paid up balance is stated as 2,30,00,000. The company had received a grant in aid for Assam Medical Services Corporation from Government from time to time amounting to Rs 8,54,00,000. The Government grant in aid cannot be converted into equity without permission of government As per AS-12 the Government grant in aid is to be shown under Capital Reserve in Balance Sheet. As per information and explanation given to us the matter of conversion of grant into equity is pending with Government. To that extent Equity capital is overstated and capital reserve is understated.

**Note No. 2.1(c) Right, Preferences and Restriction attached to Shares**

The company has one class of Equity share having a par value of Rs 100 per share. Each Shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amount, in proportion to their shareholding.

**Note No. 2.1 (d) Shares held by each shareholder holding more than 5% of shares**

Name of Shareholder	Figures as at the end of current reporting period		Figures as at the end of previous reporting period	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
Government of Assam	8.54	100%	5.50	100%

**Note No. 2.1 (e) Shareholding of Promoters & % of change during the Year**

Shares held Promoters at the end of the year	Figures as at the end of current reporting period			Figures as at the end of previous reporting period		
	No of share	% of total share	% Change	No of share	% of total share	% Change
Government of Assam	8.54	100%	-	5.50	100%	-



*Signature*  
Addl. Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD.

*Signature*  
Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD



**ASSAM MEDICAL SERVICES CORPORATION LIMITED**

**NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

		(Amount in Rupees Lakhs)	
PARTICULARS		31st March 2023	31st March 2022
<b>3 RESERVES &amp; SURPLUS</b>			
a) Capital Reserves			
As per last Balance Sheet		-	-
Add: Received during the year		-	-
Total		-	-
b) Surplus / (Deficit) in Statement of Profit & Loss			
As per last Balance Sheet		(40.89)	(19.30)
Add: Profit for the year		(196.22)	(21.59)
Closing Balance		(237.11)	(40.89)
<b>Total (a+b)</b>		<b>(237.11)</b>	<b>(40.89)</b>
<b>4 DEFERRED TAXATION</b>			
A Deferred Tax Liabilities			
Balance of DTL		6.02	-
		<b>6.02</b>	<b>-</b>
<b>5 TRADE PAYABLES</b>			
A Disclosures of amount payable			
Total outstanding dues of Micro Enterprise and Small Enterprise (note 26(1))		-	-
Total outstanding dues of creditors other than Micro Enterprise and Small Enterprise		63.22	4.99
		<b>63.22</b>	<b>4.99</b>

**B Ageing Schedule of Trade Payable is as below**

**As at March 31,2023**

Particulars	Outstanding for following periods from due date of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed dues-MSME	-	-	-	-	-
Undisputed dues-Other	63.22	-	-	-	63.22
Disputed dues-MSME	-	-	-	-	-
Disputed dues-Other	-	-	-	-	-
<b>Total Trade Payable</b>	<b>63.22</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>63.22</b>

**As at March 31,2022**

Particulars	Outstanding for following periods from due date of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed dues-MSME	-	-	-	-	-
Undisputed dues-Other	4.99	-	-	-	4.99
Disputed dues-MSME	-	-	-	-	-
Disputed dues-Other	-	-	-	-	-
<b>Total Trade Payable</b>	<b>4.99</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4.99</b>



*Signature*

**Addl. Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD.**

*Signature*

**Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD**

**ASSAM MEDICAL SERVICES CORPORATION LIMITED**

**NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

PARTICULARS	(Amount in Rupees Lakhs)	
	31st March 2023	31st March 2022
<b>6 OTHER CURRENT LIABILITIES</b>		
a Interest Payable	67.79	-
b Procurement Grant received	28,759.11	-
c Performance Security	35.04	-
d Duties & Taxes	351.24	-
e NSQ Central	129.99	-
f NSQ State	98.00	-
g EMD Deposit	59.15	-
h Recovery of Late Delivery	393.25	-
i Biman Dev Nath	-	0.04
j Salary Payable	-	0.91
k Professional Tax Payable	-	0.01
l I.T. TDS payable	-	0.16
m GST TDS	-	0.23
	<b>29,893.56</b>	<b>1.35</b>
<b>8 CAPITAL WORK IN PROGRESS (CWIP)</b>		
Opening Balance	-	201.88
Renovation of office building	-	7.69
		<b>209.58</b>
<b>9 CASH AND BANK BALANCES</b>		
A Cash and Cash Equivalents		
Cash in hand		
Balances in current account	30,317.46	290.66
	<b>30,317.46</b>	<b>290.66</b>
<b>10 SHORT TERM LOANS AND ADVANCES</b>		
a) Loans and advances to related parties		
Unsecured, considered good	-	-
b) Others		
Unsecured, considered good		
Loan/Advances to other Parties	16.29	-
	<b>16.29</b>	<b>-</b>

**10.1 Loan & Advance in the nature of loan outstanding from promoters, directors, KMPs and related parties**

Particulars	31-03-2023		31-03-2022	
	Amount	%	Amount	%
Promoters	-	-	-	-
Directors	-	-	-	-
KMPs	-	-	-	-
Loan to subsidiary Orient Knitfab Pvt Ltd	-	-	-	-
Loan to subsidiary Orient Spun Silk and Processing Mills Ltd	-	-	-	-
<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>



*[Signature]*

**Addl. Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD.**

*[Signature]*

**Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD**

ASSAM MEDICAL SERVICES CORPORATION LIMITED

NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023

7 PROPERTY, PLANT & EQUIPMENT AND DEPRECIATION (2022-23)

(Amount in Rupees Lakhs)

PARTICULARS	GROSS BLOCK			Depreciation			Net Block	
	01.04.2022	Addition/sale during the year	Total as on 31.03.2023	Upto 01.04.2022	For the Year	Total as on 31.3.2023	as on 31.03.2023	as on 31.03.2022
Office Building	3.06	209.58	212.64	0.16	3.37	3.52	209.11	2.90
Furniture & Fixture	3.57	-	3.57	0.02	0.34	0.36	3.21	3.55
Computer & Peripherals	3.66	26.84	30.50	0.21	2.19	2.40	28.11	3.45
Office Equipment	1.28	4.25	5.52	0.02	0.91	0.93	4.59	1.25
<b>Total</b>	<b>11.57</b>	<b>240.67</b>	<b>252.24</b>	<b>0.40</b>	<b>6.81</b>	<b>7.21</b>	<b>245.03</b>	<b>11.16</b>
<b>Previous Year</b>	<b>3.06</b>	<b>8.51</b>	<b>11.57</b>	<b>0.11</b>	<b>0.30</b>	<b>0.40</b>	<b>11.16</b>	<b>2.95</b>



*Pragindao*

Addl. Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD.

*[Signature]*

Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD



**ASSAM MEDICAL SERVICES CORPORATION LIMITED**

**NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

PARTICULARS	(Amount in Rupees Lakhs)	
	31st March 2023	31st March 2022
<b>11 OTHER CURRENT ASSETS</b>		
a) TCS (AY 22-23)	0.92	-
b) Advance to Sandip Dutta	-	0.23
c) Advance to BSNL	-	1.92
	<b>0.92</b>	<b>2.15</b>
<b>12 OTHER INCOME:</b>		
Interest Income		2.19
Penalty for Late Delivery	-	0.00
Interest Received on Savings Account	0.79	-
Interest Received on Savings Account (Grant In Aid)	6.90	-
Miscellaneous Income	1.02	-
	<b>8.71</b>	<b>2.19</b>
<b>13 EMPLOYEE BENEFIT EXPENSE</b>		
Remuneration to Staff	60.35	-
	<b>60.35</b>	<b>-</b>
<b>14 OTHER EXPENSES</b>		
Advertisement	59.01	9.56
Audit Fees	1.55	-
Bank Charges	-	0.01
Computer Accessorises	0.02	-
Dsc Making Chg	0.09	-
Electrical Fittings	0.24	-
Fee On Gst	0.01	-
Housekeeping Expenses	3.02	0.17
Interest On Gst	0.02	-
Meeting & Interview Expenses	2.92	-
Office Expenses	6.65	0.32
Petrol Oil & Lubricants	9.95	-
Printing And Stationery	1.49	-
Professional Fees	4.26	2.60
Repairs And Maintenance	1.13	-
Remuneration	-	2.05
Roc Expenses	0.10	0.04
Security Personal Expenses	11.11	-
Telephone & Internet Expenses	0.53	2.06
Testing Charge Of Bedsheet & Pillow	0.08	-
Travelling Expenses	3.00	-
Vehicle Hiring Expenses	20.52	-
Vehicle Expenses	-	6.34
Website Expenses	4.18	-
	<b>129.86</b>	<b>23.15</b>



*[Signature]*

**Addl. Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD.**

*[Signature]*

**Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD**

# ASSAM MEDICAL SERVICES CORPORATION LIMITED

## NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023

### 15 OTHER NOTES FORMING PART OF THE ACCOUNTS:

1 The Information required to be disclosed under section 22 of the Micro, Small and Medium Enterprises Development Act, 2006 has been determined to the extent such parties have been identified on the basis of information available with the company. There are no overdue to parties on account of principal amount and/or interest and accordingly no additional disclosure have been made.

2 Salaries includes directors remuneration on account of salary Rs Nil /-

3 Trade receivables, Trade payables, Loans & Advances and Unsecured Loans have been taken at their book value subject to confirmation and reconciliation

4 Payments to Auditors:

Auditors Remuneration	2022-2023	2021-2022
Audit Fees	25,000.00	-
Tax Audit Fees	-	-
Company Law Matters	-	-
GST	-	-
Total	25,000.00	-

5 Loans and Advances are considered good in respect of which company does not hold any security other than the personal guarantee of persons.

	(Amount in Rupees Lakhs)	
	Current Year (Rs.)	Previous Year (Rs.)
6 Earning per share		
Profit after taxation (a)	(196.22)	(21.59)
Number of ordinary shares (b)	8,54,000	5,50,000
Earning per share (face value Rs 100)		
- Basic and Diluted - (In Rs) (a)/(b)	-22.98	-3.93

	Current Year		Previous Year	
	Value (Rs)	Percentage	Value (Rs)	Percentage
7 a) Value of Stores and spare parts consumed				
i) Indigeneous	Nil	Nil	Nil	Nil
ii) Imported	Nil	Nil	Nil	Nil
b) Raw materials				
i) Indigeneous	Nil	Nil	Nil	Nil
ii) Imported	Nil	Nil	Nil	Nil
8 Value of imports calculated on CIF basis				
i) Raw Materials	Nil		Nil	
ii) Store & Spare parts	Nil		Nil	
iii) Capital Goods	Nil		Nil	
9 Expenditure in Foreign Currency				
i) Technical Services	Nil		Nil	
ii) Foreign Travelling	Nil		Nil	
iii) Other matters	Nil		Nil	
10 Earnings in Foreign Exchange	Nil		Nil	



Addl. Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD.

Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD

# ASSAM MEDICAL SERVICES CORPORATION LIMITED

## NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023

- 11 Amount remitted in foreign currency during the year on account of dividend

Nil

Nil

### 12 Related Party Disclosures

Particulars	Nature of relationship
(a) Anup Kumar Barman	Director
(b) Robin Kumar	Managing Director
(c) Pranati Majumdar	Director
(d) Niranjan Borah	Director
(e) Dinesh Kumar Verma	CFO

Nature of Transaction and Related party involved	Amount FY 22-23	Amount FY 21-22
Remuneration paid to Dinesh Kumar Verma	8,000	-
Travelling Expenses paid to Pranati Majumdar	4,260	-

- 13 Previous years figures have been regrouped where necessary to conform to this year's classification.

### 14 Contingent Liabilities (to the extent not provided for):

2022-23

2021-22

- (a) Claims against the Company not acknowledged as debts  
(b) Guarantees issues by the company to another person  
(c) Other money for which the company is contingently liable:

Nil

Nil

Nil

Nil

Nil

Nil

### Commitments:

- (a) Estimated amount of contracts remaining to be executed on capital accounts and not provided for

Nil

Nil

- (b) Uncalled liability on shares and other investments partly paid

Nil

Nil

- (c) Other Commitment

Nil

Nil

### 15 Details of dividend payment

2022-23

2021-22

- Dividends proposed to Equity Shareholders  
Dividends proposed to Preference Shareholders

Nil

Nil

N.A.

N.A.

- 16 There is no borrowing from Bank or Financial Institution

- 17 In opinion of Board, all assets other than Property, Plant and Equipment and Non Current investment have a realisable value in ordinary course of business which don't differ significantly from amount which is stated in financial statements.

- 18 Additional Regulatory Information/disclosures as required by General Instructions to Schedule III to the Companies Act, 2013 are furnished to the extent applicable to the Company.

- 19 The Company doesn't own any immovable property except office building which are self-constructed and hence no title deeds available for the same.

- 20 Company has not revalued its Property, Plant and Equipment

- 21 Capital Work in Progress: Nil



Addl. Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD.

Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD



**ASSAM MEDICAL SERVICES CORPORATION LIMITED**

**NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

22 Intangible assets under developemnt : Nil

23 Benami Transactions

No proceedings have been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder

24 The company is not required to file quarterly returns or statements of current assets with banks or financial institutions

25 Wilful Defaulter

The Company has not been a declared wilful defaulter by any bank or financial institution or other lender either during the year or earlier years

26 Relationship with Struck off Companies

The Company has not entered into any transactions with the Struck Off Companies during the year

27 Registration of charges or satisfaction with Registrar of Companies

The company has not created any charge on its asset

28 Compliance with number of layers of companies

The company does not have any investment through more than two layer of investment companies as defined under Section 2(87) (d) and section 186 of Companies Act 2013

29 Compliance with approved scheme(s) of arrangements

There is no scheme of Arrangement that has been approved by Competent Authorities in terms of Section 230 to Section 237 of Companies Act 2013

30 Loans and Advances/ Investments of Funds and Receipt funds in capacity of intermediaries

No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

No funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

31 Undisclosed income

No transaction has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

32 Corporate Social Responsibility (CSR)


The Company is not covered under provisions under Section 135

33 Details of Crypto Currency or Virtual Currency

The Company has not invested in any Crypto Currencies or Virtual Currencies during the year.



  
Addl. Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD.

  
Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD

ASSAM MEDICAL SERVICES CORPORATION LIMITED

NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023

34 RATIO ANALYSIS

Ratios	Numerator	Denominator	Current Year	Previous Year	% Variance
Current Ratio (in times)	Total Current Assets	Total Current Liabilities	1.01	46.18	-97.81%
Debt-Equity Ratio (in times)	Debt consists of Borrowings and Lease Liabilities	Total Equity	N.A	N.A	N.A
Debt Service Coverage Ratio (in times)	Earning for Debt Service = Net Profit after taxes + Non-cash operating expenses + Interest + Other non-cash adjustments	Debt service = Interest and lease payments + Principal repayments	N.A	N.A	N.A
Return on Equity Ratio (in %)	Profit after tax less Preference dividend (if any)	Equity Shareholders Fund	(0.32)	(0.04)	649.91%
Inventory Turnover Ratio	Sales	Average Inventory	N.A.	N.A.	N.A.
Trade Receivables Turnover Ratio (in times)	Revenue from operations	Average Trade Receivables	N.A.	N.A.	N.A.
Trade Payable Turnover Ratio (in times)	Total Purchases	Average Trade Payables	N.A.	N.A.	N.A.
Net capital turnover ratio	Sales	Average Working Capital	0.03	0.02	73.63%
Net Profit Ratio (in %)	Net Profit	Revenue from operations	-2251.81%	-985.36%	128.53%
Return on Capital Employed Ratio (in %)	Profit Before Interest and Tax	Capital Employed (Debt + Equity)	(0.31)	(0.04)	631.20%
Return on Investments	Income generated from Investments	Time weighted average investment	NA	NA	-



Addl. Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD

Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD

Figures used for determination of ratios					
Particulars	Current Year Fig (22-23)	Previous Year Fig (21-22)	Preceding prev yr (20-21)	Average for current year	Average for previous year
Current Assets [Note 9+10+11]	30,334.67	292.81	6.45		
Current Liabilities [Note 5+6]	29,956.70	6.34	2.82		
Debt	-	-	-		
Total Equity/Shareholders fund [Note 2+3]	616.89	509.11	-		
Earnings for Debt Service	N.A.	N.A.	-		
Debt Service	N.A.	N.A.	-		
PAT [Note 11 of PL]	-196.22	-21.59	-		
Profit before interest and tax [Note 9 of PL]	-188.30	-21.25	-		
Capital Employed [Debt + Total Equity]	616.89	509.11	-		
Sales [Note 12]	8.71	2.19	-		
Purchases	N.A.	N.A.	N.A.	N.A.	N.A.
Inventory	N.A.	N.A.	N.A.	N.A.	N.A.
Trade Receivables	N.A.	N.A.	N.A.	N.A.	N.A.
Trade Payable [Note 6]	63.22	4.99	2.78	34.10	3.89
Working Capital [Current Asset-Current Liab]	377.89	286.47	3.63	332.18	145.05

Particulars	Reasons thereof for variance
Current Ratio (in times)	The Company had surplus funds in previous year in its bank account which is to be refunded/utilized in current year against various liabilities thereby leading to variance
Debt-Equity Ratio (in times)	N.A.
Debt Service Coverage Ratio (in times)	N.A.
Return on Equity Ratio (in %)	As mention the company has incurred losses in current year which led to variance in ratio
Inventory Turnover Ratio	N.A.
Trade Receivables Turnover Ratio (in times)	N.A.
Trade Payable Turnover Ratio (in times)	N.A.
Net capital turnover ratio	As mention above due to surplus fund the current assets balance in previous year was higher as compared to current year leading variation in net capital turnover ratio
Net Profit Ratio (in %)	As mention the company has incurred losses in current year which led to variance in ratio
Return on Capital Employed Ratio (in %)	As mention the company has incurred losses in current year which led to variance in ratio



Addl. Managing Director  
ASSAM MEDICAL SERVICES

Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD



**ASSAM MEDICAL SERVICES CORPORATION LIMITED**

**NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

PARTICULARS	(Amount in Rupees Lakhs)	
	31st March 2023	31st March 2022
<b>4A DEFERRED TAXATION</b>		
Depreciation as per Income Tax Act	29.97	-
Depreciation as per Companies Act	6.81	-
Timing Difference	23.16	-
Rate of tax	0.26	0.26
Closing Balance of DTL/(DTA)	6.02	-1.90
Opening Balance of DTL/(DTA)	-1.90	-2.24
Deferred Tax transferred to PL	-7.92	-0.34
<b>5A SUNDRY CREDITORS</b>		
Assam Tribune Pvt Ltd	2.47	-
Biman Debnath & Associates	0.12	-
Dhs (Fw)	0.02	-
Ht Media	14.84	-
M.B Traders	41.16	-
Rocky Enterprise	0.03	-
Sanofi India Ltd	2.59	-
Vinayak Tours & Travels	0.46	3.46
Audit Fees Payable	1.55	-
Chaganmal Sarawagi & Sons	-	0.80
Karnal Enterprise	-	0.17
Saraighat Security Services	-	0.56
	<b>63.22</b>	<b>4.99</b>
<b>6A INTEREST PAYABLE</b>		
ASACS SB Interest Payable	0.68	-
AYUSH SB Interest Payable	1.01	-
NHM SB Interest Payable	66.10	-
	<b>67.79</b>	<b>-</b>
<b>6B PROCUREMENT GRANT RECEIVED</b>		
PROCUREMENT GRANT SNEHA SPARSHA	55.57	-
PROCUREMENT GRANT-ASSAM STATE AIDS CONTROL SOCIETY	246.35	-
PROCUREMENT GRANT AYUSH	168.48	-
PROCUREMENT GRANT ECRP II	4,548.87	-
PROCUREMENT GRANT IT	89.51	-
PROCUREMENT GRANT NHM 15TH FINANCE	6,740.95	-
PROCUREMENT GRANT NHM CENTRAL BUDGET	3,120.54	-
PROCUREMENT GRANT NHM CENTRAL BUDGET EQUIPMENT & IT	7,688.30	-
PROCUREMENT GRANT NHM STATE FREE DRUG SERVICE	6,100.54	-
	<b>28,759.11</b>	<b>-</b>



*[Signature]*  
**Addl. Managing Director**  
**ASSAM MEDICAL SERVICES**  
**CORPORATION LTD.**

*[Signature]*  
**Managing Director**  
**ASSAM MEDICAL SERVICES**  
**CORPORATION LTD**

**ASSAM MEDICAL SERVICES CORPORATION LIMITED**

**NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

PARTICULARS	(Amount in Rupees Lakhs)	
	31st March 2023	31st March 2022
<b>6C PERFORMANCE SECURITY</b>		
Abbott India Limited Pbg	0.02	-
Akums Drugs & Pharmaceuticals Ltd Pbg	0.50	-
Athenese Dx Pbg	0.03	-
Beta Drugs Limited Pbg	0.93	-
Bharat Parenterals Limited Pbg	0.06	-
Biocon Biologics Pbg	0.71	-
Cipla Ltd Pbg	0.25	-
Concord Biotech Pbg	1.36	-
Divine Laboratories Pbg	0.13	-
East African India Overseas Pbg	0.79	-
Eastern Healthcare Pbg	0.03	-
Elsai Pharmaceuticals India Pvt Ltd Pbg	0.68	-
Ferring Pharmaceutical Pbg	1.13	-
Getwell Pharmaceuticals Pbg	0.47	-
Globela Pharma Private Limited Pbg	0.01	-
Gls Pharma Limited Pbg	0.09	-
Healthium Medtech Ltd Pbg	0.69	-
India Medtronic Pvt Ltd Pbg	1.37	-
Ipca Laboratories Limited Pbg	0.01	-
Mascot Health Series Pvt Ltd Pbg	0.38	-
Med Source Pbg	0.09	-
Midas Care Pharmaceuticals Pbg	0.06	-
Midascare Pharmaceuticals Pvt Ltd Pbg	0.07	-
Naprod Lifescience Pbg	0.22	-
Om Biomedic Pvt Ltd Pbg	0.02	-
Peter Surgical Pbg	0.58	-
Plasmagen Bio Science Pvt Ltd Pbg	0.04	-
Q Line Biotech Private Limited Pbg	0.03	-
Shrinivas Polyfabric And Packwell Pvt Ltd Pbg	14.71	-
Swiss Garnier Life Science Pbg	1.49	-
Themis Medicare Limited Pbg	0.34	-
Trugen Pharmaceuticals Pvt Ltd Pbg	0.05	-
Unisur Lifecare Private Limited Pbg	0.73	-
Unisur Lifecare Pvt Ltd Pbg	6.89	-
Wilcure Remedies Pvt Ltd Pbg	0.07	-
	<b>35.04</b>	-
<b>6D DUTIES AND TAXES</b>		
TDS	1.38	-
CGST 1%	24.87	-
IGST 2%	300.04	-
PROFESSIONAL TAX	0.07	-
SGST 1%	24.87	-
	<b>351.24</b>	-



*Signature*  
**Addl. Managing Director**  
**ASSAM MEDICAL SERVICES**  
**CORPORATION LTD.**

*Signature*  
**Managing Director**  
**ASSAM MEDICAL SERVICES**  
**CORPORATION LTD**

**ASSAM MEDICAL SERVICES CORPORATION LIMITED**

**NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

(Amount in Rupees Lakhs)

PARTICULARS	31st March 2023	31st March 2022
<b>6E NSQ CENTRAL</b>		
NSQ Anamika Udyog Central	16.69	-
NSQ Ang Lifescience Central	11.37	-
NSQ Apple Formulation Central	2.70	-
NSQ Bharat Parenterals Central	2.90	-
NSQ Hab Pharmaceutical & Research Ltd Central	30.24	-
NSQ Medicamen Organics Central	4.27	-
NSQ Navkar Lifescience Central	0.63	-
NSQ Om Biomedic Central	12.70	-
NSQ Unicure Ltd Central	11.02	-
NSQ Vivek Pharmachem Central	21.49	-
NSQ Zenith Corporation Central	7.19	-
NSQ Zest Pharma Central	8.78	-
	<b>129.99</b>	-
<b>6F NSQ STATE</b>		
NSQ ANAMIKA UDYOG STATE DRUG BUDGET	48.68	-
NSQ CURETECH STATE	0.23	-
NSQ GALPHA LABORATORIES STATE	3.30	-
NSQ HAB PHARMACEUTICAL STATE	2.10	-
NSQ MASCOT HEALTH SERIES STATE	7.52	-
NSQ NAVKAR LIFESCIENCE STATE	9.87	-
NSQ OM SURGICAL INDUSTRIES STATE	8.63	-
NSQ ZENITH CORPORATION STATE	17.67	-
	<b>98.00</b>	-
<b>6G EMD DEPOSIT</b>		
AGAM PHARMACEUTICALS EMD	1.00	-
AYUSH INFOTECH EMD	1.65	-
BALAJI BAG MANUFACTURERS EMD	9.25	-
BHARAT PARENTERALS EMD	2.02	-
BIOMERIEUX INDIA PRIVATE LIMITED EMD	2.00	-
BMG Informatics EMD	1.69	-
CARE MEDICAL DEVICES LTD EMD	2.00	-
EASTERN TECHNOLOGY GROUP EMD	0.58	-
ELITE COMPUTERS AND COMMUNICATIONS EMD	25.09	-
J K COMMERCIAL EMD	1.00	-
JYOTI PHARMACEUTICALS EMD	0.40	-
MARUTI MEDITECH PVT LTD EMD	2.00	-
Mercantile Agents EMD	0.38	-
ONE TOUCH MEDICAL PRODUCTS PRIVATE EMD	2.00	-
PROGRESSIVE ENTERPRISE EMD	1.11	-
ROYAL TRADE LINKS EMD	1.00	-
VYGON INDIA PRIVATE LIMITED EMD	2.00	-
WHITE CLOUDS PVT LTD	1.00	-
Miscellaneous EMD	2.98	-
	<b>59.15</b>	-



*Deependra*  
Addl. Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD.

*Sanjib*  
Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD.



**ASSAM MEDICAL SERVICES CORPORATION LIMITED**

**NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

PARTICULARS	(Amount in Rupees Lakhs)	
	31st March 2023	31st March 2022
<b>6H RECOVERY OF LATE DELIVERY</b>		
LD ABBOTT INDIA LTD	4.65	-
LD ACULIFE HEALTHCARE PVT LTD	0.49	-
LD Admac Lifescience Baddi	0.46	-
LD AEGIS LIFE SCIENCE	0.23	-
LD AKUM DRUGS & PHARMACEUTICAL LTD	0.15	-
LD ANAMIKA UDYOG	0.65	-
LD ANG LIFESCIENCE INDIA LTD	24.90	-
LD APPLE FORMULATION PVT LTD	19.07	-
LD ASOJ SOFT CAPS PVT LTD	0.02	-
LD ATHENESE DX PVT LTD	1.49	-
LD Avantor Performance	0.77	-
LD BABU RAM OM PRAKASH	0.44	-
LD Baxter(India) Pvt Ltd	0.33	-
LD BECTON DICKINSON INDIA PVT LTD	1.23	-
LD BHARAT BIOTECH	7.32	-
LD BHARAT PARENTERALS LTD	5.56	-
LD BHARAT SERUM & VACCINE LTD	1.19	-
LD BIOGENIX IN LTD	0.02	-
LD Biological E Ltd	1.85	-
LD CADILA HEALTHCARE LTD	0.11	-
LD Care Medical Devices Ltd	1.74	-
LD Centurion Remedies Pvt Ltd	0.25	-
LD Cipla LTD	2.66	-
LD CMG BIOTECH PVT LTD	1.50	-
LD Concord Biotech Ltd	0.34	-
LD CONSERN PHARMA LTD	0.02	-
LD Cosmas Research Lab	3.78	-
LD CURETECH SKINCARE	1.87	-
LD DD Pharmaceuticals	0.00	-
LD Delux Surgical	0.41	-
LD DIVINE LABORATORIES	0.03	-
LD DR REDDYS LAB LTD	3.55	-
LD EAST AFRICAN INDIA OVERSEAS	0.70	-
LD EASTERN HEALTHCARE	0.01	-
LD EISAI PHARMACEUTICALS INDIA PVT LTD	0.03	-
LD EMCURE PHARMACEUTICALS	0.04	-
LD Fresenius Kabi India	3.56	-
LD FRESENIUS KABI ONCOLOGY LTD	0.02	-
LD FUTURA SURGICARE PVT LTD	0.17	-
LD GALAXY MEDICARE LTD	0.45	-
LD GALPHA LABORATORIES LTD	1.54	-
LD GARWARE FLUFLEX INDIA PVT LTD	0.33	-
LD GENETEX LIFESCIENCES PVT LTD	0.01	-
LD GETWELL PHARMACEUTICALS	0.06	-
LD GLENMARK PHARMACEUTICALS	3.15	-
LD GLOBAL BIO SCIENCES	0.14	-
LD GLS PHARMA LIMITED	0.64	-
LD GUFIC BIOSCIENCE	0.14	-
LD HAB PHARMACEUTICAL & RESEARCH LTD	0.08	-



*[Signature]*  
**Addl. Managing Director**  
**ASSAM MEDICAL SERVICES**  
**CORPORATION LTD.**

*[Signature]*  
**Managing Director**  
**ASSAM MEDICAL SERVICES**  
**CORPORATION LTD**

**ASSAM MEDICAL SERVICES CORPORATION LIMITED**

**NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

(Amount in Rupees Lakhs)

PARTICULARS	31st March 2023	31st March 2022
LD HALEWOOD LABORATORIES	0.18	-
LD HEALERS LAB	0.52	-
LD HELIX BIOSCIENCES	15.72	-
LD HINDUSTAN LABORATORIES	10.50	-
LD Hindustan Syringes and Medical Devices	0.36	-
LD INDIA MEDTRONIC PVT LTD	0.12	-
LD INNOVATIVE LINEN CO(P) LTD	5.42	-
LD INTAS PHARMACEUTICALS LTD	11.00	-
LD IPCA LABORATORIES LTD	0.00	-
LD ITAS G PHARMA	0.50	-
LD Jackson Laboratories	0.10	-
LD JINTECH SOLUTION	0.04	-
LD J.M Distributor	0.36	-
LD Johnson & Johnson Pvt Ltd	23.21	-
LD KISHAN CHAND & SONS	1.30	-
LD KS SURGICAL PVT LTD	6.48	-
LD LOTUS SURGICAL	0.12	-
LD Lupin Limited	0.09	-
LD MAAN PHARMACEUTICALS LTD	0.49	-
LD MACLEODS PHARMACEUTICALS LTD	0.00	-
LD MAGNA MARKETING	0.13	-
LD MAINDEOR ENTERPRISE	3.79	-
LD Marc Laboratories	3.68	-
LD MARUTI MEDITECH	1.36	-
LD MASCOT HEALTH SERIES PVT LTD	5.60	-
LD M.B TRADERS	2.64	-
LD MCO HOSPITAL PVT LTD	0.04	-
LD MED EL INDIA PVT LTD	0.64	-
LD MEDICARE PRODUCTS INC	0.36	-
LD Medico Remedies	1.54	-
LD MERIL DIAGNOSTICS PVT LTD	0.49	-
LD MICROGEN DIAGNOSTIC SYSTEM PVT LTD	0.38	-
LD Micron Pharmaceuticals	1.37	-
LD MIDAS CARE PHARMACEUTICAL PVT LTD	0.31	-
LD M.J BIOPHARMA	0.29	-
LD Modern Laboratories	0.43	-
LD MSD PHARMACEUTICALS PVT LTD	1.00	-
LD MSN LABORATORIES PVT LTD	0.16	-
LD NANDINI MEDICAL LAB PVT LTD	5.23	-
LD NAPROD LIFE SCIENCE PVT LTD	3.38	-
LD NATCO PHARMA LTD	0.03	-
LD NAVKAR LIFESCIENCE	2.06	-
LD NESTOR PHARMACEUTICALS LTD	0.01	-
LD NOVO NORDISK INDIA PVT LTD	0.57	-
LD OM BIOMEDIC PVT LTD	6.27	-
LD OMEGA PHARMA	0.00	-
LD OM SURGICAL INDUSTRIES	3.58	-
LD ONE TOUCH MEDICAL PRODUCTS PVT LTD	0.48	-
LD OTSUKA PHARMACEUTICAL INDIA PVT LTD	56.51	-
LD OVERSEAS HEALTHCARE PVT LTD	0.13	-



**Addl. Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD.**

**Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD**

**ASSAM MEDICAL SERVICES CORPORATION LIMITED**

**NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

(Amount in Rupees Lakhs)

PARTICULARS	31st March 2023	31st March 2022
LD OXALIS LABS	1.94	-
LD PANACEA BIOTECH PHARMA LTD	1.03	-
LD Paschim Barga Pharmaceutical	3.43	-
LD Paviour Pharmaceuticals Ltd	0.17	-
LD PFIZER PROCUTS INDIA PVT LTD	1.32	-
LD Plasmagen Bio Sciences Pvt Ltd	1.93	-
LD PLASTI SURGE INDUSTRIES	8.48	-
LD POLAR INDUSTRIAL CORPORATION	0.14	-
LD POLY MEDICURE LTD	2.64	-
LD Primewear Hygiene	0.09	-
LD PROTECH TELELINKS	5.43	-
LD RELIANCE LIFE SCIENCE PVT LTD	1.75	-
LD Rivpra Formulation Pvt Ltd	5.54	-
LD ROYAL SURGICARE	0.23	-
LD RPG LIFESCIENCES LIMITED	0.07	-
LD Rusan Pharma Ltd	0.01	-
LD Saar Biotech Pvt Ltd	1.75	-
LD SAI PARENTERALS	1.00	-
LD Samarth Life Science Pvt Ltd	0.02	-
LD SAM KEM	1.29	-
LD SANOFI INDIA LTD	2.41	-
LD Scott Edill Pharmacia Ltd	3.44	-
LD SD BIOSENSOR HEALTHCARE PVT LTD	0.09	-
LD SENSACORE MEDICAL INSTRUMENTATION	0.82	-
LD SHAKTI SYSTEM	0.02	-
LD SHREE RADHE HYGIENE PRODUCTS PVT LTD	2.17	-
LD SOBER CARE SURGICAL	0.64	-
LD STERIMED MEDICAL DEVICES PVT LTD	1.90	-
LD STERIMED SURGICALS INDIA PVT LTD	0.84	-
LD SUN SYNDICATE INDUSTRIES	0.28	-
LD SUNWAYS ( INDIA) PVT LTD	0.42	-
LD SUNWAYS ROHTO PHARMACEUTICAL	0.26	-
LD SURU INTERNATIONAL PVT LTD	4.66	-
LD SWISS GARNIER LIFE SCIENCE	0.13	-
LD SWISS PARENTERALS	0.19	-
LD SYNOKEM PHARMACEUTICALS LTD	15.23	-
LD SYSTRONICS	0.10	-
LD Tablets (India) Ltd	0.31	-
LD TAKEDA PHARMACEUTICALS	8.73	-
LD THEMIS MED CARE LTD	0.41	-
LD TITAN BIOTECH LTD	0.01	-
LD TRANSASIA BIO MEDICAL LTD	0.17	-
LD TROIKAA PHARMACEUTICALS	3.15	-
LD TRUGEN PHARMACEUTICALS	0.01	-
LD UNICURE INDIA LTD	4.02	-
LD UNIMARK HEALTHCARE LTD	4.58	-
LD UNIQUE BIOTECH LTD	0.62	-
LD UNISUR LIFECARE PVT LTD	0.22	-
LD VEEKAY SURGICAL PVT LTD	0.11	-
LD VENUS REMEDIES LTD	1.06	-



**Addl. Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD.**

**Managing Director  
ASSAM MEDICAL SERVICES  
CORPORATION LTD**



**ASSAM MEDICAL SERVICES CORPORATION LIMITED**

**NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH 2023**

(Amount in Rupees Lakhs)

PARTICULARS	31st March 2023	31st March 2022
LD VERVE HUMAN CARE LABORATORIES	0.24	-
LD VHB MEDI SCIENCES LIMITED	2.43	-
LD VINDAS CHEMICAL INDUSTRIES	0.03	-
LD VINS BIOPRODUCTS LTD	1.46	-
LD VIVEK PHARMACHEM INDIA LTD	2.22	-
LD WILCURE REMEDIES PVT LTD	0.06	-
LD Wilson Tapes Pvt Ltd	0.29	-
LD WINGS BIOTECH	0.05	-
LD YACCA PHARMACEUTICAL PVT LTD	0.01	-
LD ZENITH CORPORATION	5.64	-
LD ZENITH DRUGS PVT LTD	6.89	-
LD ZEST PHARMA	0.21	-
LD Zim Laboratories	0.09	-
LD ZUVIUS LIFE SCIENCE	0.29	-
	<b>393.25</b>	-
<b>9A BALANCES IN CURRENT ACCOUNT</b>		
HDFC A/C 50100549564479(STATE BUDGET)	18,326.77	-
HDFC AMSCL HOLDING A/C NO 6920	72.27	-
HDFC AMSCL NHM FUND(SB) 6268	11,156.62	-
HDFC EMD A/C 50100516234601	376.76	-
HDFC PIP SNA A/C-50100491751630	1.49	-
SBI A/C NO-37862545509	383.55	290.66
	<b>30,317.46</b>	<b>290.66</b>
<b>10B LOANS/ADVANCES TO OTHER PARTIES</b>		
Advance to BSNL	1.92	-
Advance to NHM	13.72	-
Imprest Advance to Pabitra Debnath	0.50	-
Imprest Advance to Sandip Dutta	0.15	-
	<b>16.29</b>	-



*[Signature]*  
**Addl. Managing Director**  
**ASSAM MEDICAL SERVICES**  
**CORPORATION LTD.**

*[Signature]*  
**Managing Director**  
**ASSAM MEDICAL SERVICES**  
**CORPORATION LTD**

## ASSAM MEDICAL SERVICES CORPORATION LIMITED

F.Y 2022-23

## SCHEDULES FORMING PART OF BALANCE SHEET

DEPRECIATION AS PER INCOME TAX ACT, 1961

(Amount in Rupees Lakhs)

	Fixed Assets	Gross Block					Accumulated Depreciation					Net Block	
		Balance as at 1 April 2022	Addition for more than 180 days	Addition for less than 180 days	Revaluation s/ (Impairmen ts)	Balance as at 31 March 2023	Balance as at 1 April 2022	Depreciat ion charge for the year	Adjustmen t due to revaluation s	On disposal s	Balance as at 31 March 2023	Balance as at 31st March 2023	Balance as at 31 March 2022
		(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
	Tangible Assets (10% Block)												
	Office Building	3.06	209.58			212.64	0.94	21.26			22.20	190.43	2.12
	Tangible Assets (15% Block)												
	Office Equipments	1.28	2.43	1.82		5.52	0.10	0.69	-	-	0.79	4.74	0.86
	Tangible Assets (40% Block)												
	Computer & Peripherals	3.66	4.12	22.73		30.50	1.10	7.66			8.76	21.75	2.22
	Tangible Assets (10% Block)												
	Office Furniture	3.57				3.57	0.18	0.36			0.54	3.04	3.39
	Total												
		11.57	216.12	24.55	-	252.24	2.31	29.97	-	-	32.28	219.96	8.59



*Devi Prada*  
 Addl. Managing Director  
 ASSAM MEDICAL SERVICES  
 CORPORATION LTD.

*Shrimati*  
 Managing Director  
 ASSAM MEDICAL SERVICES  
 CORPORATION LTD